Owlstone Medical, the developer of a breath-based diagnostic tool for lung cancer, is now taking aim at asthma. Owlstone Medical’s two key technologies – the Respiration Collector for In Vitro ...

Owlstone Medical, the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, ...

CAMBRIDGE, England--(BUSINESS WIRE)--Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced it has ...

Owlstone Medical has secured the first closing of its Series E financing round, securing $27m (approximately £22m) to advance the development of its Breath Biopsy platform and the commercialisation of ...

Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy ® for applications in early disease detection and precision medicine, today announced that the Cystic Fibrosis Foundation has made an ...

Owlstone Medical has announced that it has made three appointments to its senior team including business development, clinical research and manufacturing executives. The appointments follow the ...

Diagnostics firm Owlstone Medical has announced the launch of its breath biopsy kits, a new diagnostic tool capable of detecting biomarkers of disease in the breath. Cambridge-based Owlstone said the ...

CAMBRIDGE, England--(BUSINESS WIRE)--Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, announced today that it has raised $15 million (£11 million) to drive the global ...

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath Biopsy platform into ...

If successful, Thermo's mass analyser will become a standard part of Owlstone Medical’s biomarker discovery process. Owlstone Medical has announced a new collaboration with Thermo Fisher Scientific, ...